Åpne denne publikasjonen i ny fane eller vindu >>Centre for Clinical Research and Education, Region Värmland, Karlstad, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Medicinska fakulteten, Umeå centrum för molekylär medicin (UCMM).
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi. Umeå universitet, Medicinska fakulteten, Molekylär Infektionsmedicin, Sverige (MIMS).
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Umeå universitet, Medicinska fakulteten, Umeå centrum för molekylär medicin (UCMM).
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi. Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM).
Umeå universitet, Medicinska fakulteten, Umeå Centre for Microbial Research (UCMR). Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Vise andre…
2024 (engelsk)Inngår i: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 15, nr 10, artikkel-id e01303-24Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1–5) and severe COVID-19 (WHO-CPS, 6–9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.
sted, utgiver, år, opplag, sider
American Society for Microbiology, 2024
Emneord
COVID-19, hyaluronan, hyaluronic acid, SARS-CoV-2, lung impairment, 3D-lung model
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-229944 (URN)10.1128/mbio.01303-24 (DOI)001318493400001 ()39302125 (PubMedID)2-s2.0-85206959059 (Scopus ID)
Forskningsfinansiär
Swedish Heart Lung Foundation, 20200385Swedish Heart Lung Foundation, 20200325Swedish Heart Lung Foundation, 20210078Swedish Heart Lung Foundation, 20200366Swedish Heart Lung Foundation, 20210049The Kempe Foundations, JCK-1827Umeå University, 978018Umeå University, 964781Nyckelfonden, OLL-938628Nyckelfonden, OLL-961416Sjukvårdsregionala forskningsrådet Mellansverige, RFR-968856Sjukvårdsregionala forskningsrådet Mellansverige, RFR-940474Swedish Research Council, 2020-06235Swedish Research Council, 2016-06514Swedish Research Council, 2021-06602Åke Wiberg Foundation, M22-0106Magnus Bergvall Foundation, 2022-186
2024-09-232024-09-232024-10-28bibliografisk kontrollert